

Erratum

Volume 36, No. 7, page 3517: Table II should read:

Table II. *HCC characteristics.*

ID	Gender	Year	Disease	Method	Drug	Drug concentration (mg)	Size of beads (μm)	Tumor response	Procedure complications
3	m	70	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	CR	None
4	f	83	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	CR	None
5	m	61	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	PR	None
6	m	65	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	CR	None
9	m	63	HCC	LIFDOX [®]	Doxo	50	100 \pm 25	PR	None
10	m	74	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	CR	None
11	m	64	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	CR	None
13	m	55	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	CR	None
14	m	64	HCC	LIFDOX [®]	Doxo	50	200 \pm 25	PR	None
16	m	83	HCC	LIFDOX [®]	Doxo	50	400 \pm 50	PR	None

HCC, Hepatocellular carcinoma; CHOLANGIO, cholangiocarcinoma, BC-LM, breast cancer liver metastases; CRC-LM, colorectal carcinoma liver metastases; U-LM, uveal liver metastases; doxo, doxorubicin; CR, complete response; PR, partial response; LIFIRI[®], TACE with Lifepearls[®] pre-loaded with irinotecan; LIFDOX[®], TACE with Lifepearls[®] pre-loaded with doxorubicin.